BLOOMFIELD, Conn., Dec. 20, 2022 /PRNewswire/ -- Global health services company Cigna Corporation (NYSE:CI) announced today that David Cordani, chairman and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 in San Francisco, CA.
Cigna's presentation is expected to begin at approximately 5:15 p.m. ET. A live webcast of the presentation will be available at https://investors.cigna.com/events-and-presentations/default.aspx in the Investor Relations section of Cigna's website.
To listen to this presentation live on the Internet, visit https://investors.cigna.com/events-and-presentations/default.aspx at least 15 minutes prior to the presentation to download and install any necessary audio software.
Cigna Corporation is a global health services company dedicated to improving the health, well-being and peace of mind of those we serve. Cigna delivers choice, predictability, affordability and access to quality care through integrated capabilities and connected, personalized solutions that advance whole person health. All products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth companies or their affiliates and Express Scripts companies or their affiliates. Such products and services include an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits and other related products.
Cigna maintains sales capability in over 30 countries and jurisdictions, and has over 190 million customer relationships around the world. To learn more about Cigna®, including links to follow us on Facebook or Twitter, visit www.cigna.com.
Investor Relations Contact
Ralph Giacobbe
1 (860) 787-7968
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Justine Sessions
1 (860) 810-6523
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$341.85 |
| Daily Change: | 5.35 1.59 |
| Daily Volume: | 434,089 |
| Market Cap: | US$95.090B |
October 31, 2024 September 12, 2024 September 12, 2024 August 01, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
